[Effect of therapy with rosuvastatin on circulating endothelial progenitor cells in patients with chronic heart failure].
We assessed effect of therapy with HMG--CoA reductase inhibitor rosuvastatin on the number of circulating hemopoietic stem CD34+, CD133+ cells in peripheral blood of patients with systolic left ventricular dysfunction of ischemic genesis. Number of circulating hemopoietic stem CD34+, CD133+ cells in patients with chronic heart failure did not differ from their number in control group, however we revealed tendency to increase of number of endothelial CD34+, CD133+, VEGFR-2+ progenitor cells. We confirmed presence of relationship between quantity of circulating stem and progenitor cells and traditional risk factors of cardiovascular events: age, excessive body mass, arterial hypertension, and intima media thickness of common carotid arteries. Besides lipid lowering effect therapy with rosuvastatin was associated with lowering of C-reactive protein level and increase of number of circulating CD34+, CD133+ cells.
Moiseeva
O M
OM
Karelkina
E V
EV
Moroshkin
V S
VS
Seliutin
A V
AV
Shliakhto
E V
EV
D000071916:AC133 Antigen; D000328:Adult; D015703:Antigens, CD / Q000097:blood; D018952:Antigens, CD34 / Q000097:blood; D004305:Dose-Response Relationship, Drug; D004730:Endothelium, Vascular / Q000187:drug effects / Q000276:immunology / Q000473:pathology*; D005260:Female; D005464:Fluorobenzenes / Q000008:administration & dosage*; D005500:Follow-Up Studies; D006023:Glycoproteins / Q000097:blood; D006333:Heart Failure / Q000097:blood* / Q000188:drug therapy / Q000503:physiopathology; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage*; D008297:Male; D059630:Mesenchymal Stem Cells / Q000187:drug effects / Q000276:immunology / Q000473:pathology*; D008875:Middle Aged; D010455:Peptides / Q000097:blood; D011743:Pyrimidines / Q000008:administration & dosage*; D000068718:Rosuvastatin Calcium; D013318:Stroke Volume / Q000502:physiology; D013449:Sulfonamides / Q000008:administration & dosage*; D016896:Treatment Outcome
D000071916:AC133 Antigen; D015703:Antigens, CD; D018952:Antigens, CD34; D005464:Fluorobenzenes; D006023:Glycoproteins; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; C000606023:PROM1 protein, human; D010455:Peptides; D011743:Pyrimidines; D013449:Sulfonamides; D000068718:Rosuvastatin Calcium